<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">29767811</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1615-6692</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Herz</Title>
          <ISOAbbreviation>Herz</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Peripartum cardiomyopathy.</ArticleTitle>
        <Pagination>
          <StartPage>431</StartPage>
          <EndPage>437</EndPage>
          <MedlinePgn>431-437</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00059-018-4709-z</ELocationID>
        <Abstract>
          <AbstractText>Peripartum cardiomyopathy (PPCM) is a rare and potentially life-threatening disease that occurs toward the end of pregnancy or in the months following delivery in previously heart-healthy women. The incidence varies widely depending on geographical region and ethnic background, with an estimated number of 1 in 1000-1500 pregnancies in Germany. The course of the disease ranges from mild forms with minor symptoms to severe forms with acute heart failure and cardiogenic shock. The understanding of the etiology of PPCM has evolved in recent years. An oxidative stress-mediated cleaved 16-kDa fragment of the nursing hormone prolactin is thought to damage endothelial cells and cardiomyocytes. Bromocriptine, a dopamine-receptor agonist, effectively blocks prolactin release from the pituitary gland. In addition to standard heart failure therapy, this disease-specific treatment reduces morbidity and mortality in PPCM patients. This review summarizes the current knowledge on PPCM and the disease-specific treatment options.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Koenig</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hilfiker-Kleiner</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bauersachs</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. bauersachs.johann@mh-hannover.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Peripartale Kardiomyopathie.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Herz</MedlineTA>
        <NlmUniqueID>7801231</NlmUniqueID>
        <ISSNLinking>0340-9937</ISSNLinking>
      </MedlineJournalInfo>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058725" MajorTopicYN="N">Peripartum Period</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011249" MajorTopicYN="Y">Pregnancy Complications, Cardiovascular</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="Publisher" Language="ger">
        <AbstractText>Die Peripartum-Kardiomyopathie (PPCM) ist eine seltene und potenziell lebensbedrohliche Erkrankung, die gegen Ende der Schwangerschaft oder in den Folgemonaten nach Entbindung bei zuvor herzgesunden Frauen auftritt. Die Inzidenz der PPCM variiert mit deutlichen regionalen und ethnischen Unterschieden. In Deutschland beträgt die geschätzte Inzidenz etwa 1 von 1000–1500 Schwangerschaften. Der klinische Verlauf umfasst leichte Formen mit unspezifischen Symptomen bis hin zu einer schweren akuten Herzinsuffizienz mit Entwicklung eines kardiogenen Schocks. In den vergangenen Jahren ist das Stillhormon Prolaktin in den Fokus der Pathogenese der PPCM gerückt. Durch vermehrten oxidativen Stress wird eine Spaltung des Prolaktins in ein toxisches 16-kDa-Fragment induziert. Dieses schädigt sowohl Endothelzellen als auch Kardiomyozyten und resultiert in einer systolischen Herzinsuffizienz. Bromocriptin, ein Dopaminrezeptoragonist, hemmt die Freisetzung des Prolaktins aus der Hypophyse. Durch die Bromocriptinbehandlung in Kombination mit einer medikamentösen Herzinsuffizienztherapie lassen sich die Morbidität und Mortalität der PPCM senken. In der vorliegenden Übersichtsarbeit werden die aktuellen wissenschaftlichen sowie klinischen Erkenntnisse zur PPCM zusammengefasst und die spezifischen Therapieoptionen erläutert.</AbstractText>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bromocriptine</Keyword>
        <Keyword MajorTopicYN="N">Cardiomyopathies</Keyword>
        <Keyword MajorTopicYN="N">Heart failure</Keyword>
        <Keyword MajorTopicYN="N">Pregnancy complications</Keyword>
        <Keyword MajorTopicYN="N">Prolactin</Keyword>
      </KeywordList>
      <CoiStatement>T. Koenig and D. Hilfiker-Kleiner declare that they have no competing interests. J. Bauersachs received honoraria for lectures and/or consulting from Novartis, Pfizer, Vifor, Bayer, Servier, Orion, CVRx, Abiomed, Abbott/SJM/Thoratec, Medtronic/Heartware, and research support from Zoll, CVRx, Bayer, Vifor, Abiomed, Medtronic.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29767811</ArticleId>
        <ArticleId IdType="pmc">PMC6096623</ArticleId>
        <ArticleId IdType="doi">10.1007/s00059-018-4709-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s00059-018-4709-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Berg CJ, Callaghan WM, Syverson C, et al.  Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010;116:1302–1309. doi: 10.1097/AOG.0b013e3181fdfb11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/AOG.0b013e3181fdfb11</ArticleId>
            <ArticleId IdType="pubmed">21099595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collaborators GBDMM. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1775–1812. doi: 10.1016/S0140-6736(16)31470-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)31470-2</ArticleId>
            <ArticleId IdType="pmc">PMC5224694</ArticleId>
            <ArticleId IdType="pubmed">27733286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanna M, Stergiopoulos K. Pregnancy complicated by valvular heart disease: an update. J Am Heart Assoc. 2014;3:e000712. doi: 10.1161/JAHA.113.000712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.113.000712</ArticleId>
            <ArticleId IdType="pmc">PMC4309052</ArticleId>
            <ArticleId IdType="pubmed">24904015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al.  ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC) Eur Heart J. 2011;32:3147–3197. doi: 10.1093/eurheartj/ehr272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehr272</ArticleId>
            <ArticleId IdType="pubmed">21873418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Bohm M. Incidence and prevalence of pregnancy-related heart disease. Cardiovasc Res. 2014;101:554–560. doi: 10.1093/cvr/cvu012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvu012</ArticleId>
            <ArticleId IdType="pubmed">24459193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014;11:364–370. doi: 10.1038/nrcardio.2014.37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrcardio.2014.37</ArticleId>
            <ArticleId IdType="pubmed">24686946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al.  Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18:1096–1105. doi: 10.1002/ejhf.586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.586</ArticleId>
            <ArticleId IdType="pubmed">27338866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Podewski E, Libhaber E, et al.  Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013;108:366-013-0366-0369. doi: 10.1007/s00395-013-0366-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00395-013-0366-9</ArticleId>
            <ArticleId IdType="pmc">PMC3709080</ArticleId>
            <ArticleId IdType="pubmed">23812247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767–778. doi: 10.1093/eurjhf/hfq120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurjhf/hfq120</ArticleId>
            <ArticleId IdType="pubmed">20675664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Haghikia A, Nonhoff J, et al.  Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36:1090–1097. doi: 10.1093/eurheartj/ehv009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehv009</ArticleId>
            <ArticleId IdType="pmc">PMC4422973</ArticleId>
            <ArticleId IdType="pubmed">25636745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ware JS, Li J, Mazaika E, et al.  Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374:233–241. doi: 10.1056/NEJMoa1505517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1505517</ArticleId>
            <ArticleId IdType="pmc">PMC4797319</ArticleId>
            <ArticleId IdType="pubmed">26735901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearson GD, Veille JC, Rahimtoola S, et al.  Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–1188. doi: 10.1001/jama.283.9.1183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.283.9.1183</ArticleId>
            <ArticleId IdType="pubmed">10703781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolte D, Khera S, Aronow WS, et al.  Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014;3:e001056. doi: 10.1161/JAHA.114.001056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.114.001056</ArticleId>
            <ArticleId IdType="pmc">PMC4309108</ArticleId>
            <ArticleId IdType="pubmed">24901108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mcnamara DM, Elkayam U, Alharethi R, et al.  Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy) J Am Coll Cardiol. 2015;66:905–914. doi: 10.1016/j.jacc.2015.06.1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2015.06.1309</ArticleId>
            <ArticleId IdType="pmc">PMC5645077</ArticleId>
            <ArticleId IdType="pubmed">26293760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Haghikia A, Berliner D, et al.  Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38:2671–2679. doi: 10.1093/eurheartj/ehx355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehx355</ArticleId>
            <ArticleId IdType="pmc">PMC5837241</ArticleId>
            <ArticleId IdType="pubmed">28934837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bello N, Rendon IS, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:1715–1723. doi: 10.1016/j.jacc.2013.08.717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2013.08.717</ArticleId>
            <ArticleId IdType="pmc">PMC3931606</ArticleId>
            <ArticleId IdType="pubmed">24013055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al.  Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017;19:1131–1141. doi: 10.1002/ejhf.780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.780</ArticleId>
            <ArticleId IdType="pubmed">28271625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irizarry OC, Levine LD, Lewey J, et al.  Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol. 2017;2:1256–1260. doi: 10.1001/jamacardio.2017.3574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2017.3574</ArticleId>
            <ArticleId IdType="pmc">PMC5815055</ArticleId>
            <ArticleId IdType="pubmed">29049825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauersachs J. Poor outcomes in poor patients? Peripartum cardiomyopathy-not just black and white. JAMA Cardiol. 2017;2:1261–1262. doi: 10.1001/jamacardio.2017.3605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2017.3605</ArticleId>
            <ArticleId IdType="pubmed">29049487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Haghikia A, Masuko D, et al.  Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail. 2017;19:1723–1728. doi: 10.1002/ejhf.808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.808</ArticleId>
            <ArticleId IdType="pubmed">28345302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368:687–693. doi: 10.1016/S0140-6736(06)69253-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(06)69253-2</ArticleId>
            <ArticleId IdType="pubmed">16920474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mebazaa A, Seronde MF, Gayat E, et al.  Imbalanced angiogenesis in peripartum cardiomyopathy-diagnostic value of placenta growth factor. Circ J. 2017;81:1654–1661. doi: 10.1253/circj.CJ-16-1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1253/circj.CJ-16-1193</ArticleId>
            <ArticleId IdType="pubmed">28552862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patten IS, Rana S, Shahul S, et al.  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–338. doi: 10.1038/nature11040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11040</ArticleId>
            <ArticleId IdType="pmc">PMC3356917</ArticleId>
            <ArticleId IdType="pubmed">22596155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilfiker-Kleiner D, Kaminski K, Podewski E, et al.  A cathepsin D‑cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600. doi: 10.1016/j.cell.2006.12.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.12.036</ArticleId>
            <ArticleId IdType="pubmed">17289576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halkein J, Tabruyn SP, Ricke-Hoch M, et al.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123:2143–2154. doi: 10.1172/JCI64365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI64365</ArticleId>
            <ArticleId IdType="pmc">PMC3638905</ArticleId>
            <ArticleId IdType="pubmed">23619365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine RJ, Maynard SE, Qian C, et al.  Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683. doi: 10.1056/NEJMoa031884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa031884</ArticleId>
            <ArticleId IdType="pubmed">14764923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YZJ, Judge DP. The role of genetics in peripartum cardiomyopathy. J Cardiovasc Transl Res. 2017;10:437–445. doi: 10.1007/s12265-017-9764-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12265-017-9764-y</ArticleId>
            <ArticleId IdType="pubmed">28776299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauersachs J, Koenig T. Devil in disguise: hints and pitfalls in diagnosis of peripartum cardiomyopathy. Circ Heart Fail. 2018;11:e004620. doi: 10.1161/CIRCHEARTFAILURE.117.004620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.117.004620</ArticleId>
            <ArticleId IdType="pubmed">29626100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponikowski P, Voors AA, Anker SD, et al.  2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId>
            <ArticleId IdType="pubmed">27206819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stapel B, Kohlhaas M, Ricke-Hoch M, et al.  Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J. 2017;38:349–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5381590</ArticleId>
            <ArticleId IdType="pubmed">28201733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labbene I, Arrigo M, Tavares M, et al.  Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med. 2017;36:39–42. doi: 10.1016/j.accpm.2016.02.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.accpm.2016.02.009</ArticleId>
            <ArticleId IdType="pubmed">27436451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Tongers J, Berliner D, et al.  Early ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registry. Int J Cardiol. 2016;216:165–167. doi: 10.1016/j.ijcard.2016.04.143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijcard.2016.04.143</ArticleId>
            <ArticleId IdType="pubmed">27156059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Blauwet L, Tibazarwa K, et al.  Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465–1473. doi: 10.1161/CIRCULATIONAHA.109.901496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.901496</ArticleId>
            <ArticleId IdType="pubmed">20308616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J. 2017;38:2680–2682. doi: 10.1093/eurheartj/ehx428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehx428</ArticleId>
            <ArticleId IdType="pubmed">28934838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the treatment of peripartum cardiomyopathy. Card Fail Rev. 2018;4(1):46–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5971672</ArticleId>
            <ArticleId IdType="pubmed">29892477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncker D, Haghikia A, Konig T, et al.  Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014;16:1331–1336. doi: 10.1002/ejhf.188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ejhf.188</ArticleId>
            <ArticleId IdType="pubmed">25371320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncker D, Westenfeld R, Konrad T, et al.  Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol. 2017;106:582–589. doi: 10.1007/s00392-017-1090-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00392-017-1090-5</ArticleId>
            <ArticleId IdType="pmc">PMC5529484</ArticleId>
            <ArticleId IdType="pubmed">28275862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghikia A, Rontgen P, Vogel-Claussen J, et al.  Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. Eur J Heart Fail. 2015;2:139–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5054874</ArticleId>
            <ArticleId IdType="pubmed">27774259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58:659–670. doi: 10.1016/j.jacc.2011.03.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2011.03.047</ArticleId>
            <ArticleId IdType="pubmed">21816300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al.  Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2018</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29578284</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
